STOCK TITAN

Rigel Pharmaceuticals Inc. (New) - RIGL STOCK NEWS

Welcome to our dedicated page for Rigel Pharmaceuticals (New) news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals (New) stock.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a leading biotechnology company based in South San Francisco, California, dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with immune and hematologic disorders, cancer, and rare diseases. Established in 1996, Rigel has built a solid reputation in the pharmaceutical industry by focusing on the development of small-molecule drugs.

The company's flagship product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, is the only oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

REZLIDHIA (olutasidenib), another key product, is an oral small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible IDH1 mutation.

Rigel's pipeline includes a variety of promising candidates such as R289, an IRAK1/4 dual inhibitor for the treatment of lower-risk myelodysplastic syndrome (LR-MDS), R552, R835, THF-beta Inhibitors, and AZD0449 - an inhaled JAK inhibitor. The company is also exploring the potential of olutasidenib in high-grade glioma (HGG) through a collaboration with CONNECT, an international network of pediatric cancer centers.

Recent financial highlights include a reported net product sales of $104.3 million in 2023, showcasing a significant growth of 36% over the previous year. Rigel's partnership with major pharmaceutical companies like AstraZeneca for their rheumatoid arthritis drug and Grifols S.A. for delivery of drug supplies reinforces their strong market position.

In 2024, Rigel announced the acquisition of U.S. rights to GAVRETO (pralsetinib), a kinase inhibitor approved for treating metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic RET fusion-positive thyroid cancer. This acquisition aligns with Rigel's strategy to expand its hematology and oncology portfolio, leveraging its existing commercial infrastructure.

Rigel continues to focus on commercial execution, strategic collaborations, and advancing its robust pipeline to reach financial breakeven and deliver transformative treatments to underserved patient populations.

Rhea-AI Summary

Rigel Pharmaceuticals announced the commencement of a Phase 1b study for R289, an investigational IRAK1/4 dual inhibitor aimed at treating lower-risk myelodysplastic syndromes (MDS). The first patient has been dosed as part of this open-label study, which will enroll around 22 refractory or resistant MDS patients. The primary objective focuses on safety, with additional goals to assess preliminary efficacy and pharmacokinetic profiles. This study is vital for determining the recommended Phase 2 dose for future development of R289, highlighting Rigel's commitment to innovative treatments in hematology-oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.45%
Tags
-
Rhea-AI Summary

Optime Care has partnered with Rigel Pharmaceuticals to provide comprehensive patient support services for Rezlidhia™ (olutasidenib), an FDA-approved treatment for acute myeloid leukemia in patients with IDH1 mutations. This collaboration will enable enhanced patient management through services including medication fulfillment and prior authorization support. Rigel Pharmaceuticals emphasizes the importance of Optime Care's expertise in rare diseases to improve therapeutic outcomes for Rezlidhia patients. The partnership reflects a commitment to advancing treatment journeys for those affected by acute myeloid leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
partnership
-
Rhea-AI Summary

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the granting of 375,000 stock options to new employee Ray Furey, consisting of 187,500 options vesting over four years and another 187,500 options contingent on future performance conditions. This incentive aligns with NASDAQ's Listing Rule 5635(c)(4), which allows inducement awards for new hires. Rigel focuses on developing novel small molecule drugs for hematologic disorders, cancer, and rare immune diseases, enhancing its workforce to support these initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.79%
Tags
none
Rhea-AI Summary

Rigel Pharmaceuticals announced the FDA approval of REZLIDHIA (olutasidenib) for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) carrying an IDH1 mutation. This oral mIDH1 inhibitor yielded a 35% complete remission (CR) rate in a Phase 2 trial, with a median duration of response of 25.9 months. The approval is a significant development for R/R AML patients, improving treatment options. The company plans to commercialize REZLIDHIA in the U.S., enhancing their hematology-oncology portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.06%
Tags
-
Rhea-AI Summary

Rigel Pharmaceuticals announced positive early clinical data for olutasidenib, an investigational treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), published in The Lancet Haematology. The Phase 1/2 study demonstrated a 77% overall response rate for treatment-naïve AML patients receiving combination therapy and noted significant improvements in clinical efficacy endpoints. The PDUFA target action date for olutasidenib is set for February 15, 2023, with expectations for regulatory approval, enhancing its potential market impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
-
Rhea-AI Summary

Rigel Pharmaceuticals (RIGL) reported its third-quarter 2022 financial results, highlighting net product sales of TAVALISSE® at $19.2 million, a 20% increase year-over-year. Total revenues reached $22.4 million, with a net loss of $19 million, or $0.11 per share, showing improvement from a $21 million loss in Q3 2021. The FDA is reviewing the NDA for olutasidenib, with a target action date set for February 15, 2023. The company also presented promising data on olutasidenib's efficacy in AML at ASH and reported a 16% reduction in workforce, affecting 30 positions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) announced updated data from its Phase 2 study of olutasidenib for relapsed/refractory mIDH1 acute myeloid leukemia (AML). The interim analysis revealed a 35% complete remission (CR) plus complete remission with partial hematological recovery (CRh) rate and a median duration of 25.9 months. The NDA for olutasidenib is under FDA review, with a target action date of February 15, 2023. Rigel plans to present five posters at the 64th ASH Annual Meeting, highlighting its hematology-oncology portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
-
Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) announced top-line results from the FOCUS Phase 3 trial evaluating fostamatinib in high-risk COVID-19 patients. The trial did not meet the primary endpoint for statistical significance (p=0.0603) in days on oxygen by Day 29, though secondary endpoints favored fostamatinib, such as a 50% reduction in mortality (4 vs. 8 deaths). The safety profile matched prior results with no new issues. Rigel is considering next steps in collaboration with the U.S. Department of Defense.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Rigel Pharmaceuticals will release its third quarter 2022 financial results after market close on November 3, 2022. A conference call will follow at 4:30 PM ET to discuss the results and business updates. Investors can join the call by dialing 877-407-3088 or 201-389-0927, and a live webcast will be available on Rigel's Investor Relations website. The event will be archived for 90 days. Rigel focuses on developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Rigel Pharmaceuticals announced a workforce reduction of 16%, equating to 30 positions, primarily affecting development and administration. This decision follows the FDA's guidance regarding Rigel's wAIHA program, resulting in a delay in filing a supplemental New Drug Application. The workforce reduction is expected to incur a one-time severance charge of approximately $1.5 million in Q4 2022 but will reduce operating expenses by $7-$8 million annually starting in 2023. Despite these challenges, Rigel continues to pursue opportunities in its ongoing programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.05%
Tags
none

FAQ

What is the current stock price of Rigel Pharmaceuticals (New) (RIGL)?

The current stock price of Rigel Pharmaceuticals (New) (RIGL) is $17.09 as of December 20, 2024.

What is the market cap of Rigel Pharmaceuticals (New) (RIGL)?

The market cap of Rigel Pharmaceuticals (New) (RIGL) is approximately 307.0M.

What is Rigel Pharmaceuticals' core business?

Rigel Pharmaceuticals specializes in discovering and developing novel small-molecule drugs for immune and hematologic disorders, cancer, and rare diseases.

What are Rigel's primary products?

Rigel's primary products include TAVALISSE (fostamatinib) for chronic immune thrombocytopenia and REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia.

What recent acquisitions has Rigel made?

In 2024, Rigel acquired the U.S. rights to GAVRETO (pralsetinib), a treatment for metastatic RET fusion-positive non-small cell lung cancer and advanced or metastatic RET fusion-positive thyroid cancer.

Who are Rigel's key partners?

Rigel partners with companies like AstraZeneca for rheumatoid arthritis treatments and Grifols S.A. for delivery of drug supplies.

What are some of Rigel's pipeline products?

Rigel's pipeline includes R289 (IRAK1/4 dual inhibitor), R552, R835, THF-beta Inhibitors, and AZD0449 (inhaled JAK inhibitor).

Where is Rigel Pharmaceuticals headquartered?

Rigel Pharmaceuticals is headquartered in South San Francisco, California.

What financial milestones did Rigel achieve in 2023?

In 2023, Rigel achieved net product sales of $104.3 million, marking a 36% growth over the previous year.

What is the significance of REZLIDHIA?

REZLIDHIA is significant as it's an oral small-molecule inhibitor for the treatment of R/R AML with an IDH1 mutation, offering a targeted treatment option for this cancer.

What collaborations is Rigel involved in for pediatric cancer?

Rigel is collaborating with CONNECT, an international network of pediatric cancer centers, to evaluate olutasidenib in high-grade glioma (HGG).

What is the market focus for TAVALISSE?

TAVALISSE targets adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments.

Rigel Pharmaceuticals Inc. (New)

Nasdaq:RIGL

RIGL Rankings

RIGL Stock Data

307.03M
17.23M
2.18%
68.06%
2.63%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO